Fibrolamellar Cancer Foundation

Gemcitabine-Oxaliplatin-Lenvatinib (GEMOX-LEN) For Unresectable Fibrolamellar Carcinoma: Promising Results in First 16 Patients

This poster presentation outlines Rush University Medical Center’s experience in treating FLC patients with a gemcitabine-oxaliplatin-lenvatanib (GEMOX-LEN) combination. This study describes the experiences of 16 patients, most of whom had multiple prior surgeries and systemic therapies, who were judged unresectable. The Rush University team chose gemcitabine-oxaliplatin (GEMOX) based on case reports of GEMOX efficacy in …

A pilot study of a DNAJB1-PRKACA fusion kinase peptide vaccine combined with nivolumab and ipilimumab for patients with fibrolamellar hepatocellular carcinoma

In an abstract release for the the 2023 annual meeting of the Society for Immunotherapy of Cancer, the Johns Hopkins University team released the initial results of their peptide vaccine clinical trial launched in 2020. The trial investigated the potential effectiveness of a targeted vaccine against FLC’s DNAJ-PKAc driver when combined with the checkpoint inhibitors …